The patient experience (Breast Cancer Research and Treatment (2007) 105, SUPPL. 1, DOI: 10.1007/s10549-007-9703-8);The patient experience

Breast Cancer Research and Treatment

Volumn 105, Issue 1 SUPPL., 2007, Pages 91-103

  Harbeck, Nadia ^a   Haidinger, Renate ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Brustkrebs Deutschland eV   (Germany)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; Letrozole; Neoadjuvant therapy; Patient

Indexed keywords

ANASTROZOLE; LAPATINIB; LETROZOLE; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ABDOMINAL DISCOMFORT; ADJUVANT THERAPY; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTHRITIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAREGIVER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DYSPNEA; EDEMA; FATIGUE; FRACTURE; HEADACHE; HEART FAILURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INSOMNIA; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; NIGHT SWEAT; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SWEATING; TRANSIENT ISCHEMIC ATTACK; VAGINA BLEEDING; VAGINAL DRYNESS;

EID: 34948812935     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9852-9     Document Type: Erratum

References (137)

1. Lehto US, Ojanen M, Kellokumpu-Lehtinen P (2005) Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 16:805-816
2. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330:702
3. Bennett KK, Compas BE, Beckjord E, Glinder JG (2005) Self-blame and distress among women with newly diagnosed breast cancer. J Behav Med 28:313-323
4. Nosarti C, Roberts JV, Crayford T, McKenzie K, David AS (2002) Early psychological adjustment in breast cancer patients: a prospective study. J Psychosom Res 53:1123-1130
5. Koopman C, Angell K, Turner-Cobb JM, Kreshka MA, Donnelly P, McCoy R, Turkseven A, Graddy K, Giese-Davis J, Spiegel D (2001) Distress, coping, and social support among rural women recently diagnosed with primary breast cancer. Breast J 7:25-33
6. Turner J, Kelly B, Swanson C, Allison R, Wetzig N (2005) Psychosocial impact of newly diagnosed advanced breast cancer. Psychooncology 14:396-407
7. Avis NE, Crawford S, Manuel J (2005) Quality of life among younger women with breast cancer. J Clin Oncol 23:3322-3330
8. Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA (2003) Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 21:4027-4033
9. Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, Bower JE, Belin TR (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96:376-387
10. Vivar CG, McQueen A (2005) Informational and emotional needs of long-term survivors of breast cancer. J Adv Nurs 51:520-528
11. Lobb EA, Kenny DT, Butow PN, Tattersall MH (2001) Women's preferences for discussion of prognosis in early breast cancer. Health Expect 4:48-57
12. Geiger AM, Mullen ES, Sloman PA, Edgerton BW, Petitti DB (2000) Evaluation of a breast cancer patient information and support program. Eff Clin Pract 3:157-165
13. Keller JS (2006) Implementation of a prechemotherapy educational intervention for women newly diagnosed with breast cancer. Clin J Oncol Nurs 10:57-60
14. Green MJ, McInerney AM, Biesecker BB, Fost N (2001) Education about genetic testing for breast cancer susceptibility: patient preferences for a computer program or genetic counselor. Am J Med Genet 103:24-31
15. Nicolini A, Carpi A, Tarro G (2006) Biomolecular markers of breast cancer. Front Biosci 11:1818-1843
16. van de Vijver M (2005) Gene-expression profiling and the future of adjuvant therapy. Oncologist 10 (Suppl 2):30-34
17. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913-920
18. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M, Foekens JA (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62: 4617-4622
19. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
20. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A Multigene Assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
21. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272
22. Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, Bild A, Iversen ES, Huang AT, Nevins JR, West M (2004) Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 101:8431-8436
23. Adjuvant! Online. Decision making tools for health care professionals. http://www.adjuvantonline.com Cited 17 January 2007
24. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991
25. Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM (2006) A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology 15:1001-1013
26. Warren R, Eleti A (2006) Overdiagnosis and overtreatment of breast cancer: is overdiagnosis an issue for radiologists? Breast Cancer Res 8:205
27. Jones JL (2006) Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res 8:204
28. Kumar AS, Bhatia V, Henderson IC (2005) Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res 7:271-275
29. Moss S (2005) Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 7:230-234
30. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J (2005) Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 7:258-265
31. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I (2003) Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581-587
32. Whelan T, Levine M, Willan A, Gafni A, Sanders K, Mirsky D, Chambers S, O'Brien MA, Reid S, Dubois S (2004) Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA 28;292:435-441
33. Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L, Hwang YT, Silliman RA, Weeks JC, Mandelblatt JS (2002) Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol 20:1008-1016
34. Gray RE, Goel V, Fitch MI, Franssen E, Labrecque M (2002) Supportive care provided by physicians and nurses to women with breast cancer. Results from a population-based survey. Support Care Cancer 10:647-652
35. Esquivel A, Meric-Bernstam F, Bernstam EV (2006) Accuracy and self correction of information received from an internet breast cancer list: content analysis. BMJ 22;332:939-942
36. Rozmovits L, Ziebland S (2004) What do patients with prostate or breast cancer want from an Internet site? A qualitative study of information needs. Patient Educ Couns 53:57-64
37. Winzelberg AJ, Classen C, Alpers GW, Roberts H, Koopman C, Adams RE, Ernst H, Dev P, Taylor CB (2003) Evaluation of an internet support group for women with primary breast cancer. Cancer 97:1164-1173
38. Rankin N, Newell S, Sanson-Fisher R, Girgis A (2000) Consumer participation in the development of psychosocial clinical practice guidelines: opinions of women with breast cancer. Eur J Cancer Care (Engl) 9:97-104
39. Mallinger JB, Griggs JJ, Shields CG (2005) Patient-centered care and breast cancer survivors' satisfaction with information. Patient Educ Couns 57:342-349
40. Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Lakhani I, Salem B, Katz SJ (2005) Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer. Health Serv Res 40:745-767
41. Sabo B, St-Jacques N, Rayson D (2007) The decision-making experience among women diagnosed with stage I and II breast cancer. Breast Cancer Res Treat 102:51-59
42. Oskay-Oezcelik G, Lehmacher W, Mirz R, Christ H, Kaufmann M, Bamberg M, Werner L, Wallwiener D, Overkamp F, Hindenburg HJ, Sehouli J (2006) What do adjuvant and metastatic breast cancer patients (BC) expect from their doctors? Final results of a German survey in 617 patients. J Clin Oncol 24(18S):321s. Abstract 6085
43. Jansen SJ, Otten W, Stiggelbout AM (2006) Factors affecting patients' perceptions of choice regarding adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 99:35-45
44. Ashing-Giwa KT, Padilla G, Tejero J, Kraemer J, Wright K, Coscarelli A, Clayton S, Williams I, Hills D (2004) Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivors. Psychooncology 13:408-428
45. McCarthy NJ (2004) Care of the breast cancer survivor: increased survival rates present a new set of challenges. Postgrad Med 116:39-40, 42, 45-46
46. Mrozek E, Shapiro CL (2005) Survivorship and complications of treatment in breast cancer. Clin Adv Hematol Oncol 3:211-238
47. Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL, de Koning HJ; National Evaluation Team for Breast cancer screening (NETB) (2004) Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 91:861-867
48. Moss S, Waller M, Anderson TJ, Cuckle H; Trial Management Group (2005) Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 92:955-960
49. Elmore JG, Armstrong K, Lehman CD, Fletcher SW (2005) Screening for breast cancer. JAMA 293:1245-1256
50. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
51. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; for the Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757
52. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM; Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092. Erratum in: N Engl J Med 2004; 351:2461
53. Coombes RC, Paridaens R, Jassem J, Van de Velde CJ, Delozier T, Jones SE, Hall E, Kilburn LS, Snowdon CF, Bliss JM, for the Intergroup Exemestane Study (IES) (2006) First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 24(18S):933s. Abstract LBA527
54. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746
55. Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137
56. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
57. Ward SE, Viergutz G, Tormey D, deMuth J, Paulen A (1992) Patients' reactions to completion of adjuvant breast cancer therapy. Nurs Res 41:362-366
58. Green BL, Rowland JH, Krupnick JL, Epstein SA, Stockton P, Stern NM, Spertus IL, Steakley C (1998) Prevalence of posttraumatic stress disorder in women with breast cancer. Psychosomatics 39:102-111
59. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2006) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295-300
60. Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14:612-616
61. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537
62. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542
63. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690
64. Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR (2001) Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 76:199-202
65. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M (1998) Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 9:639-645
66. NCCN Practice Guidelines in Oncology-Breast Cancer. v.2.2006. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf Cited 17 January 2007
67. Grunfeld EA, Ramirez AJ, Maher EJ, Peach D, Young T, Albery IP, Richards MA (2001) Chemotherapy for advanced breast cancer: what influences oncologists' decision-making? Br J Cancer 84:1172-1178
68. Jones D, Ghersi D, Wilcken N (2006) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 19;3:CD003368
69. Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M; European Organization for Research, Treatment of Cancer Breast Cancer Group (2004) Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 22:2576-2586
70. Baldini E, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Carnino F, Gallo L, Giannessi P, Conte PF, Orlandini C, Bruzzi P (2004) Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer 91:45-49
71. Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2:CD002747
72. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461
73. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366
74. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109
75. Irish W, Sherrill B, Cole B, Gard C, Glendenning GA, Mouridsen H (2005) Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 16:1458-1462
76. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA, Lang R (2004) Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9:489-496
77. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318-2327
78. Thomas R, Godwardx S, Makris A, Bloomfieldk D, Moody AM, Williams M (2004) Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol 16:485-491
79. Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE (2005) Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 6:247-252
80. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748
81. Witters L, Engle L, Lipton A (2002) Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep 9:1163-1166
82. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43-49
83. Kaufman B (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). Presented at the 31st European Society for Medical Oncology Congress, Istanbul, Turkey, 27 September-3 October 2006. Abstract LBA2
84. Study comparing GW572016 and letrozole versus letrozole in subjects with advanced or metastatic breast cancer. http://www.clinicaltrials.gov/ct/show/ NCT00073528. Cited 17 January 2007
85. Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, McLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander ML (2005) What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 6:581-588
86. Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates AS, Simes RJ (2005) Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 16:1786-1794
87. Jansen SJ, Otten W, Stiggelbout AM (2004) Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol 22:3181-3190
88. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Dixon OM, Folkerd E, McCaig F, Cameron D, Dowsett M, Langridge C, A'Hern R, Fallowfield LJ (2006) Anastrozole and letrozole an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res Treat 100(suppl 1):S24. Abstract 105
89. Kaufmann M, Rody A (2005) Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. J Cancer Res Clin Oncol 131:487-494
90. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
91. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M; Letrozole Neo-Adjuvant Breast Cancer Study Group (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532
92. Abrial C, Mouret-Reynier MA, Cure H, Feillel V, Leheurteur M, Lemery S, Le Bouedec G, Durando X, Dauplat J, Chollet P (2005) Neoadjuvant endocrine therapy in breast cancer. Breast 15:9-19
93. Dixon JM, Love CD, Bellamy CO, Cameron DA, Leonard RC, Smith H, Miller WR (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66:191-199
94. Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM (2004) Is there an optimal duration of neoadjuvant letrozole therapy? Presented at the 27th Annual San Antonio Breast Cancer Symposium, 8-11 December 2004. Abstract 405
95. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531
96. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24:3019-3025
97. Murray J, Young O, Renshaw L, White S, Prescot RJ, Krause A, Evans DB, Salem R, Cameron D, Dowsett M, Miller WR, Dixon JM (2004) Letrozole and anastrozole: a pre-operative study of their effects on ER positive breast cancers in postmenopausal women. Presented at the 27th Annual San Antonio Breast Cancer Symposium, 8-11 December 2004. Abstract 406
98. Zhu L, Chow LW, Loo WT, Guan XY, Toi M (2004) Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 15;10:4639-4644
99. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139. Erratum in: Lancet 2002;360:1520
100. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619-629
101. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
102. Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D (2005) Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. Breast Cancer Res Treat 94(suppl 1):S10. Abstract 16
103. Bushnell CD, Goldstein LB (2004) Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63:1230-1233
104. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583
105. AGO Breast Commission (2007) Diagnostic and treatment of patients with primary and metastatic breast cancer. http://www.ago-online.de. Latest update July 17, 2007
106. Viale G, Regan M, Dell'Orto P, Del Curto B, Braye S, Orosz Z, Brown R, Olszewski WP, Knox F, Oehlschlegel C, Thürlimann B; the BIG 1-98 Collaborative International Breast Cancer Study Group (2005) Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 94(suppl 1):S13. Abstract 44
107. Wardley AM (2006) Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer 6(suppl 2):S45-S50
108. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG, the GABG (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462
109. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147
110. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R (2005) Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG Trial 8, and the ITA trial. Breast Cancer Res Treat 94(suppl 1):S11. Abstract 18
111. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, Von Minckwitz G, on behalf of the German Adjuvant Breast Cancer Group (2006) Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. J Clin Oncol 24(18S):14s. Abstract 547
112. Johnson Vickberg SM (2001) Fears about breast cancer recurrence. Cancer Pract 9:237-243
113. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA (2004) Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22:1630-1637
114. Whelan TJ, Pritchard KI (2006) Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 12(3 Pt 2):1056s-1060s
115. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931-6940
116. Glaus A, Boehme Ch, Thurlimann B, Ruhstaller T, Hsu Schmitz SF, Morant R, Senn HJ, von Moos R (2006) Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 17:801-806
117. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220
118. Thomas RJ, Marshall C, Williams M, Walker LG (2006) Switching to adjuvant letrozole improves hot flushes, mood, and quality of life in the tamoxifen intolerant subgroup. Ann Oncol 17(suppl 9):ix100. Abstract 264P
119. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629-3635
120. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836
121. Bundred N, Campbell I, Coleman R, DeBoer R, Eidtmann H, Frassolati A, Llombart A, Monnier A, Neven P, Dias R (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). Eur J Cancer Suppl 4(2):48. Abstract 12
122. Coleman RE, on behalf of the ATAC Trialists' Group (2006) Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S):5s. Abstract 511
123. Buzdar A et al behalf of the ATAC Trialists' Group (2006) Clinical features of joint symptoms observed in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S):15s. Abstract 551
124. Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371-2380
125. Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T, Paterson I (2006) Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 9:49-58
126. Burwell SR, Case LD, Kaelin C, Avis NE (2006) Sexual problems in younger women after breast cancer surgery. J Clin Oncol 24:2815-2821
127. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR (2000) Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 92:1054-1064
128. Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584-587
129. Davis SR, Goldstat R, Papalia MA, Shah S, Kulkarni J, Donath S, Bell RJ (2006) Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. Menopause 13:37-45
130. Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
131. The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643
132. McCloskey E, Eastell R, Lakner G, Miyamoto A, Clack G (2005) Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 94(suppl 1):S1001. Abstract 2052
133. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707-715
134. Paley M, Love N, Carlson R, Tripathy D, Kaderman R, Paley D, Dvorkin J, Ziel K (2005) Preferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. J Clin Oncol 23(16S):33s. Abstract 619
135. GAEA press release (2006) Large European survey reveals critical gaps in breast cancer patient education and communication. http://www.medicalnewstoday. com/medicalnews.php?newsid=53364 Cited 17 January 2007
136. Wengstrom Y, Alberto Costa, Jan Koedam, Vasoulla Georgiou (2006) Women's experience and knowledge of adjuvant Endocrine therapy (AET) for early breast cancer (bc): a European survey. Ann Oncol 17(suppl 9):ix99. Abstract 262P
137. Femara Prescribing Information (2005) Novartis